Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02006888
Recruitment Status : Completed
First Posted : December 10, 2013
Results First Posted : April 23, 2018
Last Update Posted : April 23, 2018
Sponsor:
Information provided by (Responsible Party):
ICON Bioscience Inc

Brief Summary:
The purpose of this study is to determine whether IBI-10090 injection is effective in the treatment of inflammation associated with cataract surgery.

Condition or disease Intervention/treatment Phase
Inflammation Cataracts Drug: IBI-10090 Drug: Placebo Phase 3

Detailed Description:
A double blinded randomized trial to assess the efficacy and safety of IBI-10090, in two separate doses as compared to placebo (ATEC carrier only sans dexamethasone)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 394 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Study Start Date : January 2014
Actual Primary Completion Date : October 2014
Actual Study Completion Date : October 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cataract

Arm Intervention/treatment
Experimental: IBI-10090 low dose
IBI-10090 low dose
Drug: IBI-10090
Other Name: Dexycu

Experimental: IBI-10090 med dose
IBI-10090 med dose
Drug: IBI-10090
Other Name: Dexycu

Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo




Primary Outcome Measures :
  1. Number of Participants With Anterior Chamber Cell Clearing [ Time Frame: Day 8 ]
    The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient must provide written informed consent by signing the Informed Consent approved by the Institutional Review Board (IRB).
  2. Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.
  3. The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 (with glare testing, if necessary) in the study eye and better than 20/200 in the fellow eye.
  4. The patient must be considered by the Investigator to have visual acuity potential greater than 20/30 in the study eye.
  5. The patient must have a corneal endothelial cell count by specular microscopy in the study eye of at least 2000 cells/mm2 with normal cell morphology.
  6. A female patient of childbearing potential (premenopausal by medical history) must have a negative pregnancy test on Day 0 and be using an effective method of birth control (although no birth control method is 100% effective, the following are considered effective means of contraception: surgical sterilization, use of oral contraceptives, barrier contraception using either a condom or diaphragm with spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch) from Screening for the duration of the study.
  7. The patient must be willing and able to understand and comply with the study procedures and to communicate meaningfully with study personnel.

Key Exclusion Criteria:

  1. Patients who have used any ocular, topical or oral corticosteroids within 7 days prior to Day 0.
  2. Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
  3. Patients who have received any intravitreal corticosteroid delivery vehicle (e.g., Retisert, Ozurdex, Iluvien) in the study eye at any time.
  4. Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
  5. Patients with an allergy or hypersensitivity to dexamethasone.
  6. Patients who are known steroid responders (corticosteroid-related intraocular pressure elevation in either eye).
  7. Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to Day 0.
  8. Patients who have undergone prior intraocular (non-laser) surgery in the study eye within 6 months prior to screening.
  9. Patients who have undergone prior intraocular laser surgery in the study eye within 3 months prior to screening.
  10. Patients with planned intraocular or laser surgery in the study eye for the duration of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02006888


Locations
Layout table for location information
United States, California
Hull Eye Center
Lancaster, California, United States, 93534
Sponsors and Collaborators
ICON Bioscience Inc
Investigators
Layout table for investigator information
Study Director: howard franklin, md ICON Bioscience Inc

Layout table for additonal information
Responsible Party: ICON Bioscience Inc
ClinicalTrials.gov Identifier: NCT02006888     History of Changes
Other Study ID Numbers: C13-04
First Posted: December 10, 2013    Key Record Dates
Results First Posted: April 23, 2018
Last Update Posted: April 23, 2018
Last Verified: March 2018

Keywords provided by ICON Bioscience Inc:
Inflammation
cataract surgery

Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Cataract
Pathologic Processes
Lens Diseases
Eye Diseases